Orgenesis Inc.

Orgenesis, Inc. (NASDAQ: ORGS) is a clinical-stage cell and gene therapy biopharmaceutical company focused on developing and commercializing point-of-care cell therapy manufacturing technologies that can bring autologous cell therapies — treatments using a patient's own cells — to cancer patients more rapidly and cost-effectively than conventional centralized manufacturing approaches. According to its website at orgenesis.com, the company's POCare (Point of Care) platform enables the manufacturing of personalized cell therapies directly at or near the clinical site where the patient is being treated, reducing the complex logistics, time delays, and cold chain challenges associated with shipping patient cells to centralized manufacturing facilities and returning finished cell therapy products for administration. Orgenesis's decentralized manufacturing approach could democratize access to cell therapies by reducing the manufacturing cost and time barriers that currently limit their availability to specialized academic medical centers.

Orgenesis's POCare technology platform, described at orgenesis.com, encompasses compact, automated cell therapy manufacturing systems that can be deployed in clinical settings to process patient-derived cells into therapeutic products — including CAR-T cells and other engineered immune cell therapies — using standardized, closed-system manufacturing processes that reduce contamination risk, operator variability, and the physical footprint of cell manufacturing operations. The platform's automation and standardization enable cell therapy manufacturing by clinical staff with less specialized cell manufacturing expertise than is required for conventional open-system manufacturing approaches, potentially enabling a broader range of hospitals and cancer treatment centers to offer personalized cell therapies to their patients. Orgenesis has developed partnerships with academic medical centers, cancer treatment institutions, and pharmaceutical companies to advance its POCare manufacturing platform and the cell therapy products manufactured on it.

Orgenesis is listed on the Nasdaq Stock Market and pursues its cell therapy and manufacturing technology development through a combination of proprietary development programs, licensing and partnership arrangements with therapeutic developers seeking to use the POCare platform for their cell therapy manufacturing, and clinical collaborations with medical institutions deploying the POCare platform in patient care settings. According to orgenesis.com, the company's POCare platform represents a potentially transformative approach to making personalized cell therapies more accessible to patients globally by removing the manufacturing barriers that limit their availability to research centers with specialized cell processing infrastructure. Orgenesis's combination of POCare point-of-care manufacturing technology, cell and gene therapy development focus, hospital and clinical center partnership model, and Nasdaq-listed structure reflects its positioning as an innovative biopharmaceutical company seeking to expand access to personalized cell therapies through decentralized manufacturing.